Posted by Michael Wonder on 10 Mar 2021
Vertex announces FDA fast track designation and initiation of a Phase 1/2 clinical trial for VX-880, a novel investigational cell therapy for the treatment of type 1 diabetes
10 March 2021 - VX-880 is the first investigational stem cell derived therapy utilising fully differentiated, insulin-producing pancreatic islet cells for the treatment of type 1 diabetes.
Vertex Pharmaceuticals today announced that the U.S. FDA has granted fast track Designation for VX-880 and that the company has initiated a clinical trial for VX-880 in patients who have type 1 diabetes with severe hypoglycaemia and impaired hypoglycaemic awareness.
